Analysis of DC markers revealed a higher proportion of cross‐presenting CD11c+CD8+MHCIILow and CD11c+CD8+MHCIIHigh DCs in the spleens and tumours of mice administered combination therapy (Figure 6e and f) when compared to mice in other groups. The gene discussed is ITGAX; the disease is neoplasm.